Heart Attack Research Program: Platelet Sub-Study (HARP) (HARP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03022552|
Recruitment Status : Recruiting
First Posted : January 16, 2017
Last Update Posted : September 17, 2020
|Condition or disease|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||350 participants|
|Target Follow-Up Duration:||6 Months|
|Official Title:||Heart Attack Research Program: Platelet Sub-Study (HARP); Platelet Collection for Patients With Myocardial Infarction|
|Actual Study Start Date :||July 1, 2020|
|Estimated Primary Completion Date :||June 30, 2025|
|Estimated Study Completion Date :||June 30, 2025|
Women with myocardial infarction (MI) with demonstrated non-obstructive coronary artery disease during cardiac catheterization (less than 50% blockage in any major vessel).
Women with myocardial infarction (MI) with demonstrated obstructive coronary artery disease during cardiac catheterization (50% or greater blockage in any major vessel) or previous history of percutaneous coronary intervention (PCI) or or coronary artery bypass graft (CABG).
Women with stable angina that are age and race matched to women in the MINOCA arm that are clinically referred for cardiac catheterization
- Examination of Platelet Activity Markers [ Time Frame: 1 year ]
- Examination of Markers of Cardiovascular Disease Risk [ Time Frame: 1 year ]This will include additional examination of known thrombosis, Inflammation, metabolic disease, and lipids/lipoprotein markers.
- Cellular and molecular mechanism of myocardial infarction in women [ Time Frame: 1 year ]To further investigate this mechanism, recent advances in microRNA, RNA, DNA expression profiling, and plasma and serum collections will be used.
- Examination of non-coding and coding mRNA profiles in women with MI and matched controls [ Time Frame: 4 years ]Specific transcripts associated with platelet activation, plaque destabilization, and different cardiovascular diseases will be analyzed at the genetic level.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03022552
|Contact: Jeffrey Berger, MD||212 263 firstname.lastname@example.org|
|Contact: Harmony R Reynolds, MDemail@example.com|
|United States, New York|
|NYU Langone Medical Center||Recruiting|
|New York, New York, United States, 10016|
|Contact: Jeffrey Berger, MD|
|Principal Investigator:||Harmony R Reynolds, MD||NYU Langone Medical Center|